Iovance Biotherapeutics (IOVA) EBT (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported EBT for 17 consecutive years, with -$79.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 32.45% year-over-year to -$79.7 million; the TTM figure through Mar 2026 stood at -$354.8 million (up 6.3% YoY), while the FY2025 annual figure was -$393.0 million, down 4.81% from the prior year.
• EBT retreated to -$79.7 million in Q1 2026 per IOVA's latest filing, from -$71.7 million in the prior quarter.
• Across five years, EBT topped out at -$71.7 million in Q4 2025 and bottomed at -$119.2 million in Q1 2022.
• Historically, EBT has averaged -$101.1 million across 5 years, with a median of -$105.3 million in 2022.
• Annual changes were most pronounced in 2022 — EBT sank 52.98% — and 2024, when it jumped 34.82%.
• Iovance Biotherapeutics' EBT stood at -$105.3 million in 2022, then retreated by 12.17% to -$118.1 million in 2023, then surged by 34.82% to -$77.0 million in 2024, then climbed by 6.86% to -$71.7 million in 2025, then decreased by 11.14% to -$79.7 million in 2026.
• Business Quant data shows IOVA's EBT at -$79.7 million in Q1 2026, -$71.7 million in Q4 2025, and -$93.7 million in Q3 2025.